EFFECT OF ORAL ADMINISTRATION OF MICROENCAPSULATED LACTIC ACID BACTERIA IN A METABOLIC SYNDROME MURINE MODEL

M. RUSSO, A. MARQUEZ, M.C. ABEIJÓN MUKDSI ; A. LÓPEZ-MALO; P. GAUFFIN CANO, R. MEDINA

San Miguel de Tucumán

Simposio; V International Symposium on Lactic Acid Bacteria; 2016

Metabolic syndrome (MS) is a termused in recent years for a group of risk factors including visceral obesity,hypertension, hyperglycemia and atherogenic dyslipidemia, which predispose theindividual to develop cardiovascular disease and type 2 diabetes. Feruloylesterases (FE) are enzymes that catalize the hydrolytic release of ferulic acid(FA), present in vegetable foods. FA is a phenolic acid with provenantioxidant, hypoglycemic and lipid lowering activities. Lactobacillus fermentum CRL1446 (Lf CRL1446) and Lactobacillusjohnsonii CRL1231 (Lj CRL1231)are potential probiotic strains selected for their FE activity capable ofreleasing FA in vitro. The administrationof lactic acid bacteria (LAB) with FE activity could improve metabolic markerspresent in animal models of MS. The aim of the present work was to evaluate theeffect of oral administration of spray-dried microcapsules containing Lf CRL1446 or Lj CRL1231 on metabolic markers in a mice model of MS. Six week oldmale Swiss albino mice were divided into six groups (n = 6, each) and daily fedfor a period of 7 weeks with a standard diet (control group) and ahyperlipidemic diet (MS group). Mice received by gavage three types ofmicrocapsules: I) empty (non-treated group), II) containing Lf CRL1446 (Lf group) or III) containing LjCRL1231 (Lj group). Theadministration dose was 107 CFU/day/mouse. Animals were sacrificedat week 7. Adiposity index was calculated. FE activity was determined in gutcontent using methyl ferulate as substrate. Released FA was detected by HPLC. Animalmetabolic status was evaluated by determination of plasmatic glucoseconcentration and lipid profile (total cholesterol, HDL-cholesterol, LDL-cholesterol,triglycerides). Results showed that body weight gain was higher after 7 weeksin mice from MS group, which presented an adiposity index significantly higherthan that from control group, whereas no significant differences were observedamong the three groups receiving microcapsules. Total intestinal FE activityshowed ~1.2 fold increase in mice receiving microencapsulated LAB compared tonon-treated group. Plasmatic levels of fasting glucose were higher in MS groupcompared to control group, and a significant decrease in Lf group was observed compared to non-treated mice. A significantreduction in the levels of total cholesterol, LDL-cholesterol and triglyceridesin Lf and Lj groups was also observed. According to these results, oraladministration of spray-dried microcapsules containing Lf CRL1446 and Lj CRL1231increases intestinal FE activity and induces beneficial metabolic changes for prevention/treatmentof MS.